CAPR

Capricor Therapeutics is a biotech company working on experimental cell and exosome treatments for rare diseases like Duchenne muscular dystrophy, a severe inherited muscle weakness. Their main product is Deramiocel, cells being tested in phase 3 trials (the late stage of human testing) to treat this disease. The company is also developing exosome-based vaccines, which are tiny particles that could deliver genetic material to treat various conditions. They have partnerships with major medical institutions including Johns Hopkins University and Cedars-Sinai Medical Center to help develop these…